Biologic premises of combined radiation therapy and chemotherapy in lung cancer

Hematology/Oncology Clinics of North America

Volumn 18, Issue 1, 2004, Pages 29-40

  Shibamoto, Yuta ^a   Jeremic, Branislav ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ANGIOZYME; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; BRYOSTATIN 1; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; ERLOTINIB; ETOPOSIDE; FENRETINIDE; FLAVOPIRIDOL; GEFITINIB; IMATINIB; ISIS 2503; ISIS 3521; L 778123; LOMUSTINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; OBLIMERSEN; OS 1774; PACLITAXEL; REBIMASTAT; SULINDAC SULFONE; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINDESINE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL KILLING; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; HUMAN; LUNG NON SMALL CELL CANCER; MORBIDITY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; REVIEW; SIDE EFFECT;

EID: 1042287098     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00151-5     Document Type: Review

References (28)

1. Steel G.G., Peckham M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 5:1979;85-91.
2. Dillman R.O., Seagren S.L., Propert K.J., Guerra J., Eaton W.L., Perry M.C.et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 323:1990;940-945.
3. Sause W.T., Scott C., Taylor S., Johnson D., Livingston R., Komaki R.et al. Radiation Therapy Oncology Group 88-08 and Eastern Cooperative Oncology Group 4588: preliminary results of a phase III trial in regionally advanced, unresectable nonsmall cell lung cancer. J Natl Cancer Inst. 87:1995;198-205.
4. Le Chevalier T., Arriagada R., Tarayre M., Lacombe-Terrier M.J., Laplanche A., Quoix W.et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma [letter]. J Natl Cancer Inst. 84:1992;58.
5. Schaake-Koning C., van der Bogaert W., Dalesio O., Festen J., Hoogenhout J., van Houtte P.et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 326:1992;524-530.
6. Jeremic B., Shibamoto Y., Acimovic L., Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 13:1995;452-458.
7. Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 14:1996;1065-1070.
8. Chen Y., Pandya K., Keng P.C., Johnstone D., Li J., Lee Y.-J.et al. Phase I/II clinical study of pulsed paclitaxel radiosensitization foradiotherapyhoracic malignancy: a therapeutic approach on the basis of preclinical research of human cancer cell lines. Clin Cancer Res. 9:2003;969-975.
9. Lau D., Leigh B., Gandara D., Edelman M., Morgan R., Israel V.et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol. 19:2001;442-447.
10. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S.et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 17:1999;2692-2699.
11. Furuse K., Hosoe S., Masuda N., Sugiura S., Yokota K., Ohbayashi M.et al. Impact of tumor control on survival in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent thoracic radiotherapy (TRT) and chemotherapy (CT) [abstract]. Proc Am Soc Clin Oncol. 19:2000;484a. Abstract 1893.
12. Curran W.J. Jr., Scott C., Langer C., Komaki R., Lee J.S., Hauser S.et al. Phase III comparison of sequential Vs cancer (NSCLC): initial reporadiotherapy of Radiation Therapy Oncology Group concurrent chemoradiation for pts with unresected stage III non-small cell lung (RTOG 9410) [abstract]. Proc Am Soc Clin Oncol. 19:2000;484a. Abstract 1891.
13. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol. 11:2001;290-299.
14. Raju U., Nakata E., Yang P., Newman R.A., Ang K.K., Milas L. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys. 54:2002;886-894.
15. Kishi K., Petersen S., Petersen C., Hunter N., Mason K., Masferrer J.L. et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 60:2000;1326-1331.
16. Brown J.M. Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys. 49:2001;319-326.
17. Huang S.M., Harari P.M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs. 17:1999;259-269.
18. McKenna W.G., Weiss M.C., Bakanauskas V.J., Sandler H., Kelsten M.L., Biaglow J.et al. The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys. 18:1990;849-859.
19. Bernhard E.J., McKenna W.G., Hamilton A.D., Sebti S.M., Qian Y., Wu J.M.et al. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res. 58:1998;1754-1761.
20. Ruiter G.A., Zerp S.F., Bartelink H., van Blitterswijk W.J., Verheij M. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res. 59:1999;2457-2463.
21. Held J., Schulze-Osthoff K. Potential and caveats of TRAIL in cancer therapy. Drug Resist Updat. 4:2001;243-252.
22. Nishimoto S., Hatta H., Ueshima H., Kagiya T. 1-(5′-fluoro- 6′-hydroxy-5′,6′-dihydrouracil-5′-yl)-5-fluorouracil, a novel N(1)-C(5)-linked dimer that releases 5-fluorouracil by radiation activation under hypoxic conditions. J Med Chem. 35:1992;2711-2712.
23. Shibamoto Y., Zhou L., Hatta H., Mori M., Nishimoto S. A novel class of antitumor prodrug, 1-(2′-oxopropyl)-5-fluorouracil (OFU001) that releases 5-fluorouracil upon hypoxic irradiation. Jpn J Cancer Res. 91:2000;433-438.
24. Mori M., Hatta H., Nishimoto S. Stereoelectronic effect on one-electron reductive release of 5-fluorouracil from 5-fluoro-1-(2′-oxocycloalkyl) uracils as a new class of radiation-activated antitumor prodrugs. J Org Chem. 65:2001;4641-4647.
25. Shibamoto Y., Zhou L., Hatta H., Mori M., Nishimoto S. In vivo evaluation of a novel antitumor prodrug, 1-(2′-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation. Int J Radiat Oncol Biol Phys. 49:2001;407-413.
26. Shibamoto Y., Mimasu Y., Hatta H., Nishimoto S., Nishimoto S. In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2′- deoxyuridine that are activated by hypoxic irradiation. Int J Radiat Oncol Biol Phys. 55:2003;548.
27. van Laar J.A.M., Rustum Y.M., Ackland S.P., van Groeningen C.J., Peters G.J. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer. 34:1998;296-306.
28. Shibamoto Y., Mimasu Y., Tachi Y., Hatta H., Nishimoto S. Comparison of 5-fluorouracil and 5-fluoro-2′-deoxyuridine as an effector in radiation-activated prodrug. J Chemother. 14:2002;390-396.